^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

SPR1-0117

i
Other names: SPR1-0117, SPR1
Associations
Trials
Company:
Sporos Bio
Drug class:
TEAD1 inhibitor, TEAD inhibitor, TEAD4 inhibitor
Associations
Trials
1year
A next generation TEAD inhibitor with refined isoform specificity for superior safety & efficacy (AACR 2023)
(iv) favorable ADME profile in rodents, dogs and NHPs, as well as a favorable safety profile. In sum, SPR1 presents monotherapy opportunities in ultra-responder populations based on internal bioinformatic insights, while broader potential exists as an adjuvant for precision oncology targeted therapies, particularly within the MAPK pathway and its upstream activators.
Clinical
|
YAP1 (Yes associated protein 1) • WWTR1 (WW Domain Containing Transcription Regulator 1) • TEAD1 (TEA Domain Transcription Factor 1)
|
SPR1-0117